AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24146089 — intervention group
Group type: EXPERIMENTAL
Intervention: CTGF levels in AHF patients
Number of subjects: 212
Study 24146220 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (9 mg/kg) + Gemcitabine (1000 mg/m(2)) + Irinotecan (100 mg/m(2))
Number of subjects: 35
Study 24146220 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab + Gemcitabine + Irinotecan
Number of subjects: 35
Study 24146249 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin levels <70%
Number of subjects: 823
Study 24146249 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin levels 70-80%
Number of subjects: 823
Study 24146249 — intervention group
Group type: COMPARATOR
Intervention: Antithrombin levels >80%
Number of subjects: 823
Study 24148552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily (single dose on day 1 and multiple doses on days 4-10)
Number of subjects: 14
Study 24148568 — intervention group
Group type: EXPERIMENTAL
Intervention: r-TVT
Number of subjects: 240
Study 24150470 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 24150470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24150759 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfoveal placement of active microelectronic subretinal implant
Number of subjects: 20
Study 24150759 — intervention group
Group type: EXPERIMENTAL
Intervention: Parafoveal placement of active microelectronic subretinal implant
Number of subjects: 20
Study 24151550 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester (STAEST) in soymilk-based minidrink (2.7 g/d, 65 mL/d)
Number of subjects: 56
Study 24151550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same drink without added plant stanols)
Number of subjects: 56
Study 24152822 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM)
Number of subjects: 104
Study 24152822 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory Blood Pressure Monitoring (ABPM)
Number of subjects: 104
Study 24152880 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised palliative care (SPC) plus standard treatment
Number of subjects: 300
Study 24152880 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 300
Study 24152982 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-free H2S levels in patients with vascular disease (n = 219)
Number of subjects: 219
Study 24152982 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nitric oxide (NO) levels in patients with peripheral arterial disease (PAD)
Number of subjects: 219
Study 24152982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of plasma free H2S to NO in patients with PAD
Number of subjects: 219
Study 24152982 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IL-6, ICAM-1, and TSP-1 levels
Number of subjects: 219
Study 24153343 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy product intake (highest quartile)
Number of subjects: 0
Study 24153343 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat intake (highest quartile)
Number of subjects: 0
Study 24153343 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy intake (highest quartile)
Number of subjects: 0
Study 24153346 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat dairy consumption
Number of subjects: 86
Study 24153346 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid fatty acid 17:0
Number of subjects: 86
Study 24153347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclooxygenase inhibitors (NSAIDs) >6 months
Number of subjects: 150
Study 24153347 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 150
Study 24153347 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 150
Study 24154514 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from healthcare professionals during delivery
Number of subjects: 379
Study 24154514 — intervention group
Group type: EXPERIMENTAL
Intervention: Respect shown towards the baby by healthcare professionals
Number of subjects: 379
Study 24154514 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term follow-up care received
Number of subjects: 379
Study 24154514 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically significant long-term post-traumatic stress symptoms (PTSS)
Number of subjects: 379
Study 24154514 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age as a risk factor for PTSS
Number of subjects: 379
Study 24154514 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced abortion prior to stillbirth as a risk factor for PTSS
Number of subjects: 379
Study 24154514 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parity as a risk factor for PTSS
Number of subjects: 379
Study 24154514 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding the baby as a protective factor against PTSS
Number of subjects: 379
Study 24155092 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting technique
Number of subjects: 1419
Study 24155092 — intervention group
Group type: COMPARATOR
Intervention: Conventional stenting
Number of subjects: 1419
Study 24155157 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (100-mg infusion followed by two 50-mg infusions, each administered over 30 minutes)
Number of subjects: 0
Study 24155635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus letrozole
Number of subjects: 0
Study 24155635 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 0
Study 24155635 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 0
Study 24155635 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab-anastrozole
Number of subjects: 0
Study 24156036 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy
Number of subjects: 102
Study 24156036 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy
Number of subjects: 102
Study 24156629 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health coach integration, home blood pressure monitoring, standardized care delivery processes, and improved medication adherence
Number of subjects: 0
Study 24156961 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb scaffold
Number of subjects: 30
Study 24157897 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 90
Study 24157897 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 90
Study 24157897 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol-Morphine Combination
Number of subjects: 90
Study 24157897 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol and Morphine Combination
Number of subjects: 90
Study 24158379 — intervention group
Group type: EXPERIMENTAL
Intervention: Active indoor group water-pipe smoking (WPS)
Number of subjects: 62
Study 24158379 — intervention group
Group type: COMPARATOR
Intervention: Passive indoor group water-pipe smoking (WPS)
Number of subjects: 62
Study 24158411 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab, lapatinib, and bevacizumab (trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance dose, intravenously every 3 weeks; lapatinib 1250 mg daily; bevacizumab 15 mg/kg intravenously every 3 weeks)
Number of subjects: 26
Study 24158411 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab, lapatinib, and bevacizumab
Number of subjects: 26
Study 24159060 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA plus CLOTBUST-HF device (2-hour therapeutic exposure to 2-MHz pulsed-wave ultrasound)
Number of subjects: 20
Study 24159060 — intervention group
Group type: COMPARATOR
Intervention: tPA alone (standard-dose intravenous)
Number of subjects: 20
Study 24159258 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg once daily
Number of subjects: 0
Study 24159343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue Diagnosis System (TDS)
Number of subjects: 60
Study 24159343 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 60
Study 24161160 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (25 mg once daily) co-administered with ethinylestradiol (35 μg)/norethindrone (1 mg)
Number of subjects: 18
Study 24161160 — intervention group
Group type: COMPARATOR
Intervention: Rilpivirine (25 mg once daily)
Number of subjects: 18
Study 24161161 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of tocilizumab (TCZ)
Number of subjects: 0
Study 24161161 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives (OC; norethindrone (NE) and ethinyl estradiol (EE))
Number of subjects: 0
Study 24161161 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives (OC) with or without a single dose of TCZ
Number of subjects: 0
Study 24162333 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents and young adults (AYAs) aged 16-29 years
Number of subjects: 1524
Study 24162333 — intervention group
Group type: COMPARATOR
Intervention: All age groups
Number of subjects: 1524
Study 24162791 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse antithymocyte globulin
Number of subjects: 95
Study 24162791 — intervention group
Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin
Number of subjects: 95
Study 24163067 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-Hz electromagnetic fields with strengths of up to 30 kV·m⁻¹ and 2.55 mT
Number of subjects: 110
Study 24163067 — intervention group
Group type: EXPERIMENTAL
Intervention: Programming to maximum sensitivity
Number of subjects: 110
Study 24163067 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of right atrial/right ventricular interferences
Number of subjects: 110
Study 24163385 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory II scores
Number of subjects: 283
Study 24163385 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of MSIMI-positive tasks
Number of subjects: 283
Study 24164320 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year gluten-free diet (GFD) in celiac patients
Number of subjects: 34
Study 24164320 — intervention group
Group type: EXPERIMENTAL
Intervention: Active celiac disease (ACD) patients
Number of subjects: 34
Study 24164320 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea-predominant irritable bowel syndrome (IBS-d) patients
Number of subjects: 34
Study 24164320 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study 24164965 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese adolescents (n=37)
Number of subjects: 51
Study 24164965 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese-NGT adolescents (n=22)
Number of subjects: 51
Study 24164965 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese-IGR adolescents (n=15)
Number of subjects: 51
Study 24164965 — intervention group
Group type: COMPARATOR
Intervention: Lean adolescents (n=14)
Number of subjects: 51
Study 24165027 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 5279
Study 24165027 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 5279
Study 24165027 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal hysterectomy (AH)
Number of subjects: 5279
Study 24165027 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 5279
Study 24165173 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin (100 mg once daily after a loading dose of 200 mg on the first day)
Number of subjects: 20
Study 24165173 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 20
Study 24166490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E serum levels (vit E/chol)
Number of subjects: 566
Study 24166490 — intervention group
Group type: EXPERIMENTAL
Intervention: History of coronary heart disease
Number of subjects: 566
Study 24166490 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 566
Study 24166490 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vit E/chol quartiles
Number of subjects: 566
Study 24166490 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-BLED scores
Number of subjects: 566
Study 24166890 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued medical therapy (CMT) for a mean of 7.1 months
Number of subjects: 31
Study 24167727 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-controlled pressure algometry on the vastus lateralis muscle
Number of subjects: 28
Study 24167727 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-controlled pressure algometry
Number of subjects: 28
Study 24167727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injections
Number of subjects: 28
Study 24168104 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum regimens
Number of subjects: 3508
Study 24168104 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-platinum regimens
Number of subjects: 3508
Study 24168104 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens with bevacizumab
Number of subjects: 3508
Study 24168104 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational regimens
Number of subjects: 3508
Study 24168104 — intervention group
Group type: EXPERIMENTAL
Intervention: Best supportive care
Number of subjects: 3508
Study 24168104 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe adverse events (AEs)
Number of subjects: 3508
Study 24168522 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-neurofeedback treatment
Number of subjects: 41
Study 24168522 — intervention group
Group type: COMPARATOR
Intervention: Placebo-neurofeedback treatment
Number of subjects: 41
Study 24170105 — intervention group
Group type: EXPERIMENTAL
Intervention: Total 25(OH)D
Number of subjects: 47
Study 24170105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailable 25(OH)D/Total 25(OH)D
Number of subjects: 47
Study 24170105 — intervention group
Group type: EXPERIMENTAL
Intervention: VDBP
Number of subjects: 47
Study 24170283 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacryoliths
Number of subjects: 86
Study 24170610 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0449 150 mg/day (days 1-28, 28-day cycle)
Number of subjects: 45
Study 24171147 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 32 mg/d and Bupropion 360 mg/d (NB32) with dietary and behavioral counseling
Number of subjects: 25
Study 24171941 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive imagery cognitive bias modification (CBM)
Number of subjects: 29
Study 24171941 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined positive imagery CBM and internet cognitive behavioural therapy (iCBT)
Number of subjects: 29
Study 24171941 — intervention group
Group type: COMPARATOR
Intervention: Control CBM and iCBT
Number of subjects: 29
Study 24172190 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrium
Number of subjects: 22
Study 24172190 — intervention group
Group type: COMPARATOR
Intervention: Left atrium
Number of subjects: 22
Study 24172304 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-wk energy-restricted, high-protein diet
Number of subjects: 50
Study 24172304 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-wk weight maintenance
Number of subjects: 50
Study 24172304 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics (plasma insulin, IL-6, adipose tissue inflammation, Lactobacillus/Leuconostoc/Pediococcus numbers)
Number of subjects: 50
Study 24172304 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight regain after energy restriction
Number of subjects: 50
Study 24172304 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian network modeling
Number of subjects: 50
Study 24173203 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG 2940nm laser associated with amorolfine lacquer
Number of subjects: 0
Study 24173203 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24173271 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 238
Study 24173271 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic patients
Number of subjects: 238
Study 24173967 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (70 mg daily) in combination with capecitabine (850 mg/m² twice daily, days 1-14), oxaliplatin (130 mg/m² on day 1), and bevacizumab (7.5 mg/kg on day 1), every 3 weeks
Number of subjects: 22
Study 24173967 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (50 mg bid)
Number of subjects: 22
Study 24173967 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (70 mg daily)
Number of subjects: 22
Study 24173967 — intervention group
Group type: EXPERIMENTAL
Intervention: CapeOx/bevacizumab
Number of subjects: 22
Study 24174627 — intervention group
Group type: EXPERIMENTAL
Intervention: hIL-6 plus vIL-6
Number of subjects: 21
Study 24174627 — intervention group
Group type: COMPARATOR
Intervention: hIL-6 only
Number of subjects: 21
Study 24174627 — intervention group
Group type: EXPERIMENTAL
Intervention: vIL-6 only
Number of subjects: 21
Study 24174627 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hIL-6 and vIL-6
Number of subjects: 21
Study 24175592 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 82
Study 24175592 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 82
Study 24175721 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine fumarate (quetiapine XR) adjunct to index antidepressant therapy
Number of subjects: 0
Study 24175721 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine fumarate (quetiapine XR)
Number of subjects: 0
Study 24175721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24175720 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine fumarate (quetiapine XR)
Number of subjects: 0
Study 24175720 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 0
Study 24175720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24176441 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset atrial fibrillation (AF) > 30 s
Number of subjects: 277
Study 24176797 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 100
Study 24176797 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 24176798 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaiac-based faecal occult blood test
Number of subjects: 6793
Study 24176798 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori stool antigen test
Number of subjects: 6793
Study 24176798 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemical test
Number of subjects: 6793
Study 24176798 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori antigen test
Number of subjects: 6793
Study 24176990 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 2011 classification
Number of subjects: 9219
Study 24176990 — intervention group
Group type: COMPARATOR
Intervention: GOLD 2007 classification
Number of subjects: 9219
Study 24176990 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 ≥50% predicted
Number of subjects: 9219
Study 24176990 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 <50% predicted
Number of subjects: 9219
Study 24177180 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-OX40 monoclonal antibody (mAb)
Number of subjects: 30
Study 24177377 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone therapy
Number of subjects: 15
Study 24178625 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe OSA (apnea-hypopnea index > 15)
Number of subjects: 93
Study 24178625 — intervention group
Group type: COMPARATOR
Intervention: No to mild OSA
Number of subjects: 93
Study 24178625 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe OSA
Number of subjects: 93
Study 24179294 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic snoring
Number of subjects: 1673
Study 24179294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy-onset snoring
Number of subjects: 1673
Study 24180494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg once daily
Number of subjects: 449
Study 24182742 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost with sofZia
Number of subjects: 40
Study 24183338 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive coronary artery bypass grafting
Number of subjects: 91
Study 24184254 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVR) using MitraClip
Number of subjects: 141
Study 24184736 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks until week 52
Number of subjects: 89
Study 24184736 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 89
Study 24184983 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate treatment
Number of subjects: 5
Study 24186563 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 29620
Study 24186563 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) and age
Number of subjects: 29620
Study 24186906 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely immunocompromised individuals with influenza
Number of subjects: 0
Study 24186906 — intervention group
Group type: COMPARATOR
Intervention: Nonimmunocompromised individuals with influenza
Number of subjects: 0
Study 24186912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Stroke (IS)
Number of subjects: 2979
Study 24186912 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient Ischemic Attack (TIA)
Number of subjects: 2979
Study 24186912 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter hyperintensities
Number of subjects: 2979
Study 24186912 — intervention group
Group type: EXPERIMENTAL
Intervention: Old microbleeds
Number of subjects: 2979
Study 24188056 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (lobectomy and extended procedures)
Number of subjects: 3508
Study 24188056 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (mostly palliative)
Number of subjects: 3508
Study 24188056 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic treatment
Number of subjects: 3508